MedTrace Logo

Comparison of Exenatide vs. Biphasic Insulin Aspart 30 on Glucose Variability in Type 2 Diabetes

NCT02449603 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2018-11-14

No results posted yet for this study

Summary

This is a multi-centre, open-label, randomized, parallel trial to compare the effect of Exenatide versus Biphasic insulin Aspart 30 on glucose variability and inflammatory markers in type 2 diabetes mellitus (T2DM) patients inadequately controlled with metformin monotherapy.

Conditions

Interventions

DRUG

Exenatide

DRUG

Biphasic insulin Aspart 30

Sponsors & Collaborators

  • Air Force Military Medical University, China

    collaborator OTHER

  • First Affiliated Hospital Xi'an Jiaotong University

    collaborator OTHER

  • Second Affiliated Hospital of Xi'an Jiaotong University

    collaborator OTHER

  • Shaanxi Provincial People's Hospital

    collaborator OTHER

  • Chang'An Hospital

    collaborator OTHER

  • Xi'an Gaoxin Hospital

    collaborator OTHER

  • Xi'an Central Hospital

    collaborator OTHER

  • Shaanxi Aerospace Hospital

    collaborator UNKNOWN

  • Xijing Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2018-04-30
Completion
2018-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02449603 on ClinicalTrials.gov